Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 1/2015

01-02-2015 | Leading Article

Caregiver Preferences for Emerging Duchenne Muscular Dystrophy Treatments: A Comparison of Best-Worst Scaling and Conjoint Analysis

Authors: Ilene L. Hollin, Holly L. Peay, John F. P. Bridges

Published in: The Patient - Patient-Centered Outcomes Research | Issue 1/2015

Login to get access

Abstract

Background

Through Patient-Focused Drug Development, the US Food and Drug Administration (FDA) documents the perspective of patients and caregivers and are currently conducting 20 public meetings on a limited number of disease areas. Parent Project Muscular Dystrophy (PPMD), an advocacy organization for Duchenne muscular dystrophy (DMD), has demonstrated a community-engaged program of preference research that would complement the FDA’s approach.

Objective

Our objective was to compare two stated-preference methods, best-worst scaling (BWS) and conjoint analysis, within a study measuring caregivers’ DMD-treatment preferences.

Methods

Within one survey, two preference-elicitation methods were applied to 18 potential treatments incorporating six attributes and three levels. For each treatment profile, caregivers identified the best and worst feature and intention to use the treatment. We conducted three analyses to compare the elicitation methods using parameter estimates, conditional attribute importance and policy simulations focused on the 18 treatment profiles. For each, concordance between the results was compared using Spearman’s rho.

Results

BWS and conjoint analysis produced similar parameter estimates (p < 0.01); conditional attribute importance (p < 0.01); and policy simulations (p < 0.01). Greatest concordance was observed for the benefit and risk parameters, with differences observed for nausea and knowledge about the drug—where a lack of monotonicity was observed when using conjoint analysis.

Conclusions

The observed concordance between approaches demonstrates the reliability of the stated-preference methods. Given the simplicity of combining BWS and conjoint analysis on single profiles, a combination approach is easily adopted. Minor irregularities for the conjoint-analysis results could not be explained by additional analyses and needs to be the focus of future research.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93.PubMedCrossRef Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93.PubMedCrossRef
2.
go back to reference Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926–9.PubMedCrossRef Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926–9.PubMedCrossRef
3.
go back to reference Center for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5–24 years—Four states, 2007. MMWR Morb Wkly Rep. 2009; 58:1119–22. Center for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5–24 years—Four states, 2007. MMWR Morb Wkly Rep. 2009; 58:1119–22.
4.
go back to reference Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord. 1991;1(1):19–29.PubMedCrossRef Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord. 1991;1(1):19–29.PubMedCrossRef
5.
go back to reference Pangalila RF, van den Bos GA, Stam HJ, van Exel NJA, Brouwer WB, Roebroeck ME. Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy. Disabil Rehabil. 2012;34(12):988–96.PubMedCrossRef Pangalila RF, van den Bos GA, Stam HJ, van Exel NJA, Brouwer WB, Roebroeck ME. Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy. Disabil Rehabil. 2012;34(12):988–96.PubMedCrossRef
6.
go back to reference Kenneson A, Bobo JK. The effect of caregiving on women in families with Duchenne/Becker muscular dystrophy. Health Soc Care Commun. 2010;18(5):520–8.CrossRef Kenneson A, Bobo JK. The effect of caregiving on women in families with Duchenne/Becker muscular dystrophy. Health Soc Care Commun. 2010;18(5):520–8.CrossRef
7.
go back to reference Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49(3):431–8.PubMedCrossRef Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49(3):431–8.PubMedCrossRef
8.
go back to reference Ouyang L, Grosse SD, Kenneson A. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. J Child Neurol. 2008;23(8):883-8. Ouyang L, Grosse SD, Kenneson A. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. J Child Neurol. 2008;23(8):883-8.
9.
go back to reference Ouyang L, Grosse SD, Fox MH, Bolen J. A national profile of health care and family impacts of children with muscular dystrophy and special health care needs in the United States. J Child Neurol. 2012;27(5):569–76.PubMedCrossRef Ouyang L, Grosse SD, Fox MH, Bolen J. A national profile of health care and family impacts of children with muscular dystrophy and special health care needs in the United States. J Child Neurol. 2012;27(5):569–76.PubMedCrossRef
10.
go back to reference Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve. 2007;36(4):424–35.PubMedCrossRef Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve. 2007;36(4):424–35.PubMedCrossRef
11.
go back to reference Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2–4 April 2004, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(8):526–34.PubMedCrossRef Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2–4 April 2004, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(8):526–34.PubMedCrossRef
12.
go back to reference Biggar W, Harris V, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disord. 2006;16(4):249–55.CrossRef Biggar W, Harris V, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disord. 2006;16(4):249–55.CrossRef
13.
go back to reference Govoni A, Magri F, Brajkovic S, Zanetta C, Faravelli I, Corti S, et al. Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Cell Mol Life Sci. 2013;70(23):4585–602.PubMedCrossRef Govoni A, Magri F, Brajkovic S, Zanetta C, Faravelli I, Corti S, et al. Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Cell Mol Life Sci. 2013;70(23):4585–602.PubMedCrossRef
14.
go back to reference Parent Project Muscular Dystrophy. Putting Patients First: Recommendations to speed responsible access to new therapies for Duchenne muscular dystrophy and other rare, serious and life-threatening neurologic disorders. Hackensack; 2013. Parent Project Muscular Dystrophy. Putting Patients First: Recommendations to speed responsible access to new therapies for Duchenne muscular dystrophy and other rare, serious and life-threatening neurologic disorders. Hackensack; 2013.
15.
go back to reference Parent Project Muscular Dystrophy. Guidance for Industry: Duchenne Muscular Dystrophy Developing Drugs for Treatment over the Spectrum of Disease. Hackensack; 2014. Parent Project Muscular Dystrophy. Guidance for Industry: Duchenne Muscular Dystrophy Developing Drugs for Treatment over the Spectrum of Disease. Hackensack; 2014.
17.
go back to reference Mullard A. Patient-focused drug development programme takes first steps. Nat Rev Drug Discov. 2013;12(9):651–2.PubMedCrossRef Mullard A. Patient-focused drug development programme takes first steps. Nat Rev Drug Discov. 2013;12(9):651–2.PubMedCrossRef
18.
go back to reference “Prescription Drug User Fee Act Patient-Focused Drug Development; Announcement of Disease Areas for Meetings Conducted in Fiscal Years 2013–2015”. Federal Register 2013; 78:21613–4. “Prescription Drug User Fee Act Patient-Focused Drug Development; Announcement of Disease Areas for Meetings Conducted in Fiscal Years 2013–2015”. Federal Register 2013; 78:21613–4.
19.
go back to reference Peay HL, Hollin I, Fischer R, Bridges JF. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther. 2014;36(5):624–37.PubMedCrossRef Peay HL, Hollin I, Fischer R, Bridges JF. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther. 2014;36(5):624–37.PubMedCrossRef
20.
go back to reference Louviere JJ, Flynn TN. Using best-worst scaling choice experiments to measure public perceptions and preferences for healthcare reform in Australia. Patient. 2010;3(4):275–83.PubMedCrossRef Louviere JJ, Flynn TN. Using best-worst scaling choice experiments to measure public perceptions and preferences for healthcare reform in Australia. Patient. 2010;3(4):275–83.PubMedCrossRef
21.
go back to reference Molassiotis A, Emsley R, Ashcroft D, Caress A, Ellis J, Wagland R, et al. Applying best-worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. Lung Cancer. 2012;77(1):199–204.PubMedCrossRef Molassiotis A, Emsley R, Ashcroft D, Caress A, Ellis J, Wagland R, et al. Applying best-worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. Lung Cancer. 2012;77(1):199–204.PubMedCrossRef
22.
go back to reference Marti J. A best-worst scaling survey of adolescents’ level of concern for health and non-health consequences of smoking. Soc Sci Med. 2012;75(1):87–97.PubMedCrossRef Marti J. A best-worst scaling survey of adolescents’ level of concern for health and non-health consequences of smoking. Soc Sci Med. 2012;75(1):87–97.PubMedCrossRef
23.
go back to reference Flynn TN, Louviere JJ, Peters TJ, Coast J. Estimating preferences for a dermatology consultation using best-worst scaling: comparison of various methods of analysis. BMC Med Res Methodol. 2008;8(1):76.PubMedCentralPubMedCrossRef Flynn TN, Louviere JJ, Peters TJ, Coast J. Estimating preferences for a dermatology consultation using best-worst scaling: comparison of various methods of analysis. BMC Med Res Methodol. 2008;8(1):76.PubMedCentralPubMedCrossRef
24.
25.
go back to reference Coast J, Salisbury C, De Berker D, Noble A, Horrocks S, Peters T, et al. Preferences for aspects of a dermatology consultation. Br J Dermatol. 2006;155(2):387–92.PubMedCrossRef Coast J, Salisbury C, De Berker D, Noble A, Horrocks S, Peters T, et al. Preferences for aspects of a dermatology consultation. Br J Dermatol. 2006;155(2):387–92.PubMedCrossRef
26.
27.
go back to reference Finn A, Louviere JJ. Determining the appropriate response to evidence of public concern: the case of food safety. J Public Policy Market. 1992:12–25. Finn A, Louviere JJ. Determining the appropriate response to evidence of public concern: the case of food safety. J Public Policy Market. 1992:12–25.
28.
go back to reference Marley AA, Louviere JJ. Some probabilistic models of best, worst, and best-worst choices. J Math Psychol. 2005;49(6):464–80.CrossRef Marley AA, Louviere JJ. Some probabilistic models of best, worst, and best-worst choices. J Math Psychol. 2005;49(6):464–80.CrossRef
29.
go back to reference Bridges J, Kinter E, Kidane L, Heinzen R, McCormick C. Things are looking up since we started listening to patients: recent trends in the application of conjoint analysis in health 1970–2007. Patient. 2008;1(4):273–82.PubMedCrossRef Bridges J, Kinter E, Kidane L, Heinzen R, McCormick C. Things are looking up since we started listening to patients: recent trends in the application of conjoint analysis in health 1970–2007. Patient. 2008;1(4):273–82.PubMedCrossRef
30.
go back to reference Flynn TN. Valuing citizen and patient preferences in health: recent developments in three types of best-worst scaling. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):259–67.PubMedCrossRef Flynn TN. Valuing citizen and patient preferences in health: recent developments in three types of best-worst scaling. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):259–67.PubMedCrossRef
31.
go back to reference Ryan M, Watson V, Amaya-Amaya M. Methodological issues in the monetary valuation of benefits in healthcare. Expert Rev Pharmacoecon Outcomes Res. 2003;3(6):717–27.PubMedCrossRef Ryan M, Watson V, Amaya-Amaya M. Methodological issues in the monetary valuation of benefits in healthcare. Expert Rev Pharmacoecon Outcomes Res. 2003;3(6):717–27.PubMedCrossRef
32.
go back to reference Louviere JJ, Islam T. A comparison of importance weights and willingness-to-pay measures derived from choice-based conjoint, constant sum scales and best-worst scaling. J Bus Res. 2008;61(9):903–11.CrossRef Louviere JJ, Islam T. A comparison of importance weights and willingness-to-pay measures derived from choice-based conjoint, constant sum scales and best-worst scaling. J Bus Res. 2008;61(9):903–11.CrossRef
33.
34.
go back to reference Srinivasan V. A conjunctive-compensatory approach to the self-explication of multiattributed preferences. Dec Sci. 1988;19(2):295–305.CrossRef Srinivasan V. A conjunctive-compensatory approach to the self-explication of multiattributed preferences. Dec Sci. 1988;19(2):295–305.CrossRef
35.
go back to reference Jaeger SR, Jørgensen AS, Aaslyng MD, Bredie WL. Best–worst scaling: an introduction and initial comparison with monadic rating for preference elicitation with food products. Food Qual Prefer. 2008;19(6):579–88.CrossRef Jaeger SR, Jørgensen AS, Aaslyng MD, Bredie WL. Best–worst scaling: an introduction and initial comparison with monadic rating for preference elicitation with food products. Food Qual Prefer. 2008;19(6):579–88.CrossRef
36.
go back to reference Cohen S, Orme B. What’s your preference? Market Res. 2004;16(2):32–7. Cohen S, Orme B. What’s your preference? Market Res. 2004;16(2):32–7.
37.
go back to reference Cohen S, editor. Maximum difference scaling: improved measures of importance and preference for segmentation. Sawtooth Software Conference Proceedings, Sawtooth Software, Inc; 2003. Cohen S, editor. Maximum difference scaling: improved measures of importance and preference for segmentation. Sawtooth Software Conference Proceedings, Sawtooth Software, Inc; 2003.
38.
go back to reference Potoglou D, Burge P, Flynn T, Netten A, Malley J, Forder J, et al. Best–worst scaling vs. discrete choice experiments: an empirical comparison using social care data. Soc Sci Med. 2011;72(10):1717–27.PubMedCrossRef Potoglou D, Burge P, Flynn T, Netten A, Malley J, Forder J, et al. Best–worst scaling vs. discrete choice experiments: an empirical comparison using social care data. Soc Sci Med. 2011;72(10):1717–27.PubMedCrossRef
39.
go back to reference Flynn TN, Louviere JJ, Peters TJ, Coast J. Best–worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171–89.PubMedCrossRef Flynn TN, Louviere JJ, Peters TJ, Coast J. Best–worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171–89.PubMedCrossRef
40.
go back to reference Bridges JF, Kinter ET, Schmeding A, Rudolph I, Mühlbacher A. Can patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks? Patient. 2011;4(4):267–75.PubMedCrossRef Bridges JF, Kinter ET, Schmeding A, Rudolph I, Mühlbacher A. Can patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks? Patient. 2011;4(4):267–75.PubMedCrossRef
41.
go back to reference Kuhfeld W. Orthogonal arrays [TS-723]. Cary: SAS [online]. 2010. Kuhfeld W. Orthogonal arrays [TS-723]. Cary: SAS [online]. 2010.
42.
go back to reference Kinter ET, Prior TJ, Carswell CI, Bridges JF. A comparison of two experimental design approaches in applying conjoint analysis in patient-centered outcomes research. Patient. 2012;5(4):279–94.PubMedCrossRef Kinter ET, Prior TJ, Carswell CI, Bridges JF. A comparison of two experimental design approaches in applying conjoint analysis in patient-centered outcomes research. Patient. 2012;5(4):279–94.PubMedCrossRef
43.
go back to reference Bridges JF, Kinter ET, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients. Patient. 2008;1(4):273–82.PubMedCrossRef Bridges JF, Kinter ET, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients. Patient. 2008;1(4):273–82.PubMedCrossRef
44.
go back to reference Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13.
45.
go back to reference Carson RT, Hanemann WM, Kopp RJ, Jon AK, Robert Cameron M, Presser S et al. Referendum design and contingent valuation: the NOAA panel’s no-vote recommendation. Rev Econ Stat. 1998;80(2):335–8. Carson RT, Hanemann WM, Kopp RJ, Jon AK, Robert Cameron M, Presser S et al. Referendum design and contingent valuation: the NOAA panel’s no-vote recommendation. Rev Econ Stat. 1998;80(2):335–8.
46.
go back to reference Groothuis PA, Whitehead JC. Does don’t know mean no? Analysis of “don’t know” responses in dichotomous choice contingent valuation questions. Appl Econ. 2002;34(15):1935–40.CrossRef Groothuis PA, Whitehead JC. Does don’t know mean no? Analysis of “don’t know” responses in dichotomous choice contingent valuation questions. Appl Econ. 2002;34(15):1935–40.CrossRef
47.
go back to reference McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press; 1974. p. 105–42. McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press; 1974. p. 105–42.
Metadata
Title
Caregiver Preferences for Emerging Duchenne Muscular Dystrophy Treatments: A Comparison of Best-Worst Scaling and Conjoint Analysis
Authors
Ilene L. Hollin
Holly L. Peay
John F. P. Bridges
Publication date
01-02-2015
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 1/2015
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-014-0104-x

Other articles of this Issue 1/2015

The Patient - Patient-Centered Outcomes Research 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.